These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11596270)

  • 41. The effect of antipyrine and rifampin on the metabolism of diazepam.
    Ohnhaus EE; Brockmeyer N; Dylewicz P; Habicht H
    Clin Pharmacol Ther; 1987 Aug; 42(2):148-56. PubMed ID: 3608348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetic analysis of enterogastric circulation of diazepam in rabbits].
    Ma YM; Sun RY
    Yao Xue Xue Bao; 1993; 28(9):651-4. PubMed ID: 8010009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diazinon toxicity affects histophysiological and biochemical parameters in rabbits.
    Yehia MA; El-Banna SG; Okab AB
    Exp Toxicol Pathol; 2007 Nov; 59(3-4):215-25. PubMed ID: 17933502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diazepam interaction with antituberculosis drugs.
    Ochs HR; Greenblatt DJ; Roberts GM; Dengler HJ
    Clin Pharmacol Ther; 1981 May; 29(5):671-8. PubMed ID: 7214796
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
    Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
    Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of rifampin, phenobarbital pretreatment, and acetylator phenotype on acetylisoniazid metabolism in the rabbit.
    Thomas BH; Zeitz W; Whitehouse LW
    Can J Physiol Pharmacol; 1987 Mar; 65(3):419-23. PubMed ID: 3580961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vibration stress and pharmacokinetics of rifampicin.
    Lavický J; Rasková H
    Arzneimittelforschung; 1989 Oct; 39(10):1240-1. PubMed ID: 2610715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A report on 10 cases of enlargement of mediastinal lymph nodes occurring during RFP and INH treatment (author's transl)].
    Sun DQ
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1981 Oct; 4(5):262-4. PubMed ID: 7341164
    [No Abstract]   [Full Text] [Related]  

  • 52. [Hepato-biliary effects of the combination rifampicin-isoniazid. I. Histological study in rats].
    Hugues FC; Marche C; Marche J
    Therapie; 1969; 24(5):899-906. PubMed ID: 5364210
    [No Abstract]   [Full Text] [Related]  

  • 53. [Effect of rifampin, isoniazid and streptomycin on E receptors of T cells].
    Du BY; Zhang JY
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1986 Dec; 9(6):348-9, 382. PubMed ID: 3495419
    [No Abstract]   [Full Text] [Related]  

  • 54. [Pharmacokinetic interactions between dihydralazine and INH in rabbits].
    Siegmund W; Zschiesche M; Schröder L; Franke G; Hüller H
    Pharmazie; 1988 Jan; 43(1):53-4. PubMed ID: 3375310
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pharmacokinetics of rifampicin in experimental animals and in man].
    Curci G; Ninni A
    Lotta Tuberc; 1971; 41(3):354-66. PubMed ID: 5291093
    [No Abstract]   [Full Text] [Related]  

  • 56. Second peak of plasma diazepam concentration and enterogastric circulation.
    Ma YM; Sun RY
    Zhongguo Yao Li Xue Bao; 1993 May; 14(3):218-21. PubMed ID: 8237395
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: A review.
    Zhuang X; Li L; Liu T; Zhang R; Yang P; Wang X; Dai L
    Front Pharmacol; 2022; 13():1037814. PubMed ID: 36299895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The modification of energy metabolism of Ehrlich-ascites tumours by INH as well as by a combination of INH with x-irradiation].
    Moritz R; Wagner H
    Radiol Diagn (Berl); 1966; 7(5):627-30. PubMed ID: 5975468
    [No Abstract]   [Full Text] [Related]  

  • 59. Acetylhydrazine hepatotoxicity.
    Bahri AK; Chiang CS; Timbrell JA
    Toxicol Appl Pharmacol; 1981 Sep; 60(3):561-9. PubMed ID: 7292494
    [No Abstract]   [Full Text] [Related]  

  • 60. Isoniazid-induced hepatic steatosis in rabbits: an explanation for susceptibility and its antagonism by pyridoxine hydrochloride.
    Whitehouse LW; Tryphonas L; Paul CJ; Solomonraj G; Thomas BH; Wong LT
    Can J Physiol Pharmacol; 1983 May; 61(5):478-87. PubMed ID: 6883201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.